Skip to main content
Top
Published in: Annals of Hematology 10/2017

01-10-2017 | Original Article

Clinical dissection of thrombotic microangiopathy

Authors: Eunjeong Kang, Shin Hye Yoo, Doyeun Oh, Kwon Wook Joo, Yon Su Kim, Sung-Soo Yoon, Inho Kim, Seonyang Park, Hajeong Lee, Youngil Koh

Published in: Annals of Hematology | Issue 10/2017

Login to get access

Abstract

Differential treatment strategies are applied in thrombotic microangiopathy (TMA) according to the sub-classifications. Hence, it is worthwhile to overview clinical manifestations and outcomes of overall TMA patients according to sub-classifications. We analyzed TMA patients whose serum lactate dehydrogenase levels >250 IU/L, with the presence of schistocytes in their peripheral blood smear, or with typical vascular pathologic abnormalities in their renal biopsy. We compared clinical manifestations including overall survival (OS) and renal survival according to TMA causes. A total of 117 TMA patients (57 primary and 60 secondary TMA) were analyzed. Renal symptom was the most common manifestation in whole patients, while renal function at diagnosis was worst in pregnancy-related TMA group. Primary TMA patients had more frequent CNS symptom and hematologic manifestation compared to secondary TMAs. Among secondary TMAs, pregnancy- and HSCT-related TMA patients showed prevalent hemolytic features. During 150.2 months of follow-up, 5-year OS rate was 64.8%. Poor prognostic factors included older age, combined hematologic and solid organ malignancies, lower hemoglobin levels, and lower serum albumin levels. There was no significant difference in OS between primary and secondary TMAs. Seventy-eight percent of patients experienced AKI during TMA. Five-year death-censored renal survival rate was poor with only 69.2%. However, excellent renal outcome was observed in pregnancy-associated TMA. TMA showed various clinical manifestations according to their etiology. Notably, both OS and renal survival were poor regardless of their etiologies except pregnancy-associated TMA. Physicians should differentiate a variety of TMA categories and properly manage this complex disease entity.
Appendix
Available only for authorised users
Literature
1.
3.
5.
go back to reference Scully M, Cataland S, Coppo P et al (2017) Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 15:312–322CrossRefPubMed Scully M, Cataland S, Coppo P et al (2017) Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 15:312–322CrossRefPubMed
6.
go back to reference Shah N, Rutherford C, Matevosyan K et al (2013) Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol 163:514–519CrossRefPubMed Shah N, Rutherford C, Matevosyan K et al (2013) Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol 163:514–519CrossRefPubMed
7.
go back to reference Jang MJ, Chong SY, Kim IH et al (2011) Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience. Int J Hematol 93:163–169CrossRefPubMed Jang MJ, Chong SY, Kim IH et al (2011) Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience. Int J Hematol 93:163–169CrossRefPubMed
8.
go back to reference Group KDIGOKAKIW (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Inter (Suppl.): 1–138 Group KDIGOKAKIW (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Inter (Suppl.): 1–138
9.
go back to reference von Baeyer H (2002) Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher 6:320–328CrossRef von Baeyer H (2002) Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher 6:320–328CrossRef
10.
go back to reference Saultz JN, Wu HM, Cataland S (2015) Headache prevalence following recovery from TTP and aHUS. Ann Hematol 94:1473–1476CrossRefPubMed Saultz JN, Wu HM, Cataland S (2015) Headache prevalence following recovery from TTP and aHUS. Ann Hematol 94:1473–1476CrossRefPubMed
11.
go back to reference Martinez MT, Bucher C, Stussi G et al (2005) Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 36:993–1000CrossRefPubMed Martinez MT, Bucher C, Stussi G et al (2005) Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 36:993–1000CrossRefPubMed
12.
go back to reference Jodele S, Laskin BL, Dandoy CE et al (2015) A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 29:191–204CrossRefPubMed Jodele S, Laskin BL, Dandoy CE et al (2015) A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 29:191–204CrossRefPubMed
13.
go back to reference Hosler GA, Cusumano AM, Hutchins GM (2003) Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 127:834–839PubMed Hosler GA, Cusumano AM, Hutchins GM (2003) Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 127:834–839PubMed
14.
go back to reference Eremina V, Cui S, Gerber H et al (2006) Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 17:724–735CrossRefPubMed Eremina V, Cui S, Gerber H et al (2006) Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol 17:724–735CrossRefPubMed
15.
16.
go back to reference Noris M, Remuzzi G (2010) Thrombotic microangiopathy after kidney transplantation. Am J Transplant 10:1517–1523CrossRefPubMed Noris M, Remuzzi G (2010) Thrombotic microangiopathy after kidney transplantation. Am J Transplant 10:1517–1523CrossRefPubMed
18.
go back to reference Nayer A, Asif A (2016) Atypical hemolytic-uremic syndrome: a clinical review. Am J Ther 23:e151–e158CrossRefPubMed Nayer A, Asif A (2016) Atypical hemolytic-uremic syndrome: a clinical review. Am J Ther 23:e151–e158CrossRefPubMed
19.
go back to reference Dahlan R, Sontrop JM, Li L et al (2015) Primary and secondary thrombotic microangiopathy referred to a single plasma exchange center for suspected thrombotic thrombocytopenic purpura: 2000-2011. Am J Nephrol 41:429–437CrossRefPubMed Dahlan R, Sontrop JM, Li L et al (2015) Primary and secondary thrombotic microangiopathy referred to a single plasma exchange center for suspected thrombotic thrombocytopenic purpura: 2000-2011. Am J Nephrol 41:429–437CrossRefPubMed
20.
go back to reference Uderzo C, Bonanomi S, Busca A et al (2006) Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 82:638–644CrossRefPubMed Uderzo C, Bonanomi S, Busca A et al (2006) Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 82:638–644CrossRefPubMed
21.
go back to reference Laskin BL, Goebel J, Davies SM, Jodele S (2011) Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 118:1452–1462CrossRefPubMed Laskin BL, Goebel J, Davies SM, Jodele S (2011) Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 118:1452–1462CrossRefPubMed
22.
go back to reference Karthikeyan V, Parasuraman R, Shah V et al (2003) Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am J Transplant 3:1289–1294CrossRefPubMed Karthikeyan V, Parasuraman R, Shah V et al (2003) Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am J Transplant 3:1289–1294CrossRefPubMed
23.
go back to reference de Fontbrune FS, Galambrun C, Sirvent A et al (2015) Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation 99:1953–1959CrossRefPubMed de Fontbrune FS, Galambrun C, Sirvent A et al (2015) Use of eculizumab in patients with allogeneic stem cell transplant-associated thrombotic microangiopathy: a study from the SFGM-TC. Transplantation 99:1953–1959CrossRefPubMed
24.
go back to reference Bridoux F, Vrtovsnik F, Noel C et al (1998) Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival. Nephrol Dial Transplant 13:298–304CrossRefPubMed Bridoux F, Vrtovsnik F, Noel C et al (1998) Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival. Nephrol Dial Transplant 13:298–304CrossRefPubMed
25.
go back to reference Zafrani L, Mariotte E, Darmon M et al (2015) Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity. J Thromb Haemost 13:380–389CrossRefPubMed Zafrani L, Mariotte E, Darmon M et al (2015) Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity. J Thromb Haemost 13:380–389CrossRefPubMed
26.
go back to reference Caprioli J, Noris M, Brioschi S et al (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267–1279CrossRefPubMedPubMedCentral Caprioli J, Noris M, Brioschi S et al (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267–1279CrossRefPubMedPubMedCentral
27.
go back to reference Ritz E, Orth SR (1999) Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341:1127–1133CrossRefPubMed Ritz E, Orth SR (1999) Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 341:1127–1133CrossRefPubMed
28.
go back to reference Krolewski M, Eggers PW, Warram JH (1996) Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study. Kidney Int 50:2041–2046CrossRefPubMed Krolewski M, Eggers PW, Warram JH (1996) Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study. Kidney Int 50:2041–2046CrossRefPubMed
29.
30.
go back to reference Frimat L, Briancon S, Hestin D et al (1997) IgA nephropathy: prognostic classification of end-stage renal failure. L’Association des Nephrologues de l'Est. Nephrol Dial Transplant 12:2569–2575CrossRefPubMed Frimat L, Briancon S, Hestin D et al (1997) IgA nephropathy: prognostic classification of end-stage renal failure. L’Association des Nephrologues de l'Est. Nephrol Dial Transplant 12:2569–2575CrossRefPubMed
33.
go back to reference Jin DC, Yun SR, Lee SW et al (2015) Lessons from 30 years’ data of Korean end-stage renal disease registry, 1985-2015. Kidney Res Clin Pract 34:132–139CrossRefPubMedPubMedCentral Jin DC, Yun SR, Lee SW et al (2015) Lessons from 30 years’ data of Korean end-stage renal disease registry, 1985-2015. Kidney Res Clin Pract 34:132–139CrossRefPubMedPubMedCentral
34.
go back to reference Vilalta R, Lara E, Madrid A et al (2012) Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol 27:2323–2326CrossRefPubMedPubMedCentral Vilalta R, Lara E, Madrid A et al (2012) Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol 27:2323–2326CrossRefPubMedPubMedCentral
35.
go back to reference Gediz F, Payzin BK, Ecemis S et al (2016) Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: a single center experience from Turkey. Transfus Apher Sci 55:357–362CrossRefPubMed Gediz F, Payzin BK, Ecemis S et al (2016) Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: a single center experience from Turkey. Transfus Apher Sci 55:357–362CrossRefPubMed
36.
go back to reference George JN, Al-Nouri ZL (2012) Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematol Am Soc Hematol Educ Program 2012:604–609 George JN, Al-Nouri ZL (2012) Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Hematol Am Soc Hematol Educ Program 2012:604–609
Metadata
Title
Clinical dissection of thrombotic microangiopathy
Authors
Eunjeong Kang
Shin Hye Yoo
Doyeun Oh
Kwon Wook Joo
Yon Su Kim
Sung-Soo Yoon
Inho Kim
Seonyang Park
Hajeong Lee
Youngil Koh
Publication date
01-10-2017
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 10/2017
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-017-3063-1

Other articles of this Issue 10/2017

Annals of Hematology 10/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.